Persistent URL of this record https://hdl.handle.net/1887/3593869
In Collections
This item can be found in the following collections:
Response to letter entitled re: UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients Is it time for everyone treated with irinotecan to be tested for UGT1A1 gene polymorphism?
- All authors
- Hulshof, E.C.; With, M. de; Creemers, G.J.; Guchelaar, H.J.; Mathijssen, R.H.; Gelderblom, H.; Deenen, M.J.
- Date
- 2022-07-03
- Volume
- 172
- Pages
- 231 - 233